RxDoctor Payments Data

Elena Feldman, OD

Optometrist · Brooklyn, NYNPI 1679526040

Payments from drug & device makers

$3,791in general payments, 2019–2025

Across 126 payments — averaging $30.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$486
  • Alcon$480
  • Johnson & Johnson Vision Care, Inc.$431
  • AbbVie$366
  • Eyevance Pharmaceuticals LLC$359
  • Novartis$279
  • plus $1K from 11 others

What the payments were for

  • Food & beverage$3,75299%
  • Gifts$391%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,791 in reported general payments places this provider in the 90th percentile of 2,743 optometrist providers in New York.

See all optometrist providers in New York

Medicare billing

Part B allowed, 2024
$479,316
Medicare patients
808
Services billed
8,577

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine602$416,449
XiidraLifitegrast359$261,374
LumiganBimatoprost193$94,273
Cyclosporine221$77,207
VyzultaLatanoprostene Bunod164$60,980
XdemvyLotilaner18$32,124
ZerviateCetirizine Hcl74$31,786
MieboPerfluorohexyloctane/Pf14$28,182
RocklatanNetarsudil Mesylat/Latanoprost55$28,148
TobradexTobramycin/Dexamethasone105$27,143
CombiganBrimonidine Tartrate/Timolol54$23,863
TyrvayaVarenicline Tartrate22$18,534
CequaCyclosporine21$16,366
AzoptBrinzolamide20$11,272
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol69$9,306

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$366$537,629861 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo$486$350,537537 claims
Eyevance Pharmaceuticals LLCZerviate, Tobradex St$359$36,56095 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$223$33,92871 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$225$32,12418 claims
AlconAzopt, Simbrinza$480$18,27339 claims
Sun Pharmaceutical Industries Inc.Cequa$198$16,36621 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Prolensa$97$11,67760 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,743 optometrist providers in New York.

Other optometrist in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →